Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
PaperCitations, authors & open-access status
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 108 citations, 2022 year and closed oa status.
108
Citations
2022
Year
closed
OA Status